Shares of Discovery Laboratories Inc. (NASDAQ:WINT) rose 3.7% during mid-day trading on Wednesday . The company traded as high as $2.91 and last traded at $2.81, with a volume of 214,735 shares trading hands. The stock had previously closed at $2.71.

Separately, Zacks Investment Research raised Discovery Laboratories from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research report on Thursday, June 23rd.

The stock’s market capitalization is $23.59 million. The stock’s 50 day moving average price is $2.21 and its 200-day moving average price is $2.20.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/discovery-laboratories-inc-wint-stock-price-up-3-7.html

Discovery Laboratories (NASDAQ:WINT) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($1.29) earnings per share for the quarter, topping the consensus estimate of ($1.64) by $0.35. Discovery Laboratories had a negative net margin of 6,229.49% and a negative return on equity of 2,977.02%. Equities analysts forecast that Discovery Laboratories Inc. will post ($5.87) EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of WINT. Sabby Management LLC bought a new position in Discovery Laboratories during the second quarter valued at $866,000. FMR LLC acquired a new stake in shares of Discovery Laboratories during the second quarter valued at approximately $438,000. BlackRock Institutional Trust Company N.A. acquired a new stake in shares of Discovery Laboratories during the second quarter valued at approximately $367,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Discovery Laboratories during the second quarter valued at approximately $384,000. Hedge funds and other institutional investors own 41.05% of the company’s stock.

Discovery Laboratories Company Profile

Windtree Therapeutics, Inc, formerly Discovery Laboratories, Inc, is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment.

5 Day Chart for NASDAQ:WINT

Receive News & Ratings for Discovery Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Discovery Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.